I8B-MC-ITSZ - ClinicalTrials.gov - NCT04585776
I8B-MC-ITSZ - ClinicalTrials.gov - NCT04585776
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year
Participants must be using Dexcom G5 or G6 Continuous Glucose Monitoring (CGM) and with a total CGM use ≥ 6 months in the prior year
Participants must have been on the same type of short acting insulin (Humalog U-100 or Novolog) for at least 30 days prior to screening
Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening
Participants must NOT
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening
Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening
Participants must not be taking certain diabetes medications that are not allowed for study participation
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY9000014, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
34
Trial Dates
October 2020 - March 2021
Trial Phase
2
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year
Participants must be using Dexcom G5 or G6 Continuous Glucose Monitoring (CGM) and with a total CGM use ≥ 6 months in the prior year
Participants must have been on the same type of short acting insulin (Humalog U-100 or Novolog) for at least 30 days prior to screening
Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening
Participants must NOT
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening
Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening
Participants must not be taking certain diabetes medications that are not allowed for study participation
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY9000014, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
34
Trial Dates
October 2020 - March 2021
Trial Phase
2
Trial Locations
Hide locations not currently recruiting